Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine
January 05, 2021 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine Agreement provides a framework for future clinical...
Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases
November 18, 2020 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases Investor support further endorsement of vaccine development strategy...
Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells
September 15, 2020 07:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells First detailed, empirical analysis of Class 1 epitopes presented by...
Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells
September 15, 2020 02:00 ET
|
Emergex Vaccines Holding Ltd
PRESS RELEASE Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells First detailed, empirical analysis of Class 1 epitopes presented by...